经导管卵圆孔未闭封堵术后残余分流影响偏头痛疗效评估的研究进展

doi:10.3969/j.issn.1004-583X.2026.04.015

摘要/Abstract

摘要：

卵圆孔未闭是偏头痛,尤其是先兆型偏头痛的潜在危险因素,经导管卵圆孔未闭封堵术为此类患者提供重要的治疗选择。然而,术后残余分流的存在是影响其长期疗效的关键临床问题。目前研究对于残余分流的发生率、检测手段及其对偏头痛症状改善的确切影响尚未形成一致结论,其潜在的血流动力学与生化机制亦待阐明。本文旨在综述该领域的研究现状,系统分析残余分流对偏头痛预后的影响,探讨其发生的影响因素与可能的优化干预策略,以期为提升封堵术治疗偏头痛的临床疗效提供理论依据与实践指导。

关键词: 卵圆孔, 未闭, 经导管卵圆孔未闭封堵术, 残余分流, 偏头痛, 疗效评估

中图分类号:

常冠楠, 孙瑛, 王玉, 刘志刚. 经导管卵圆孔未闭封堵术后残余分流影响偏头痛疗效评估的研究进展[J]. 临床荟萃, 2026, 41(4): 380-384.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.04.015

https://www.lchc.cn/CN/Y2026/V41/I4/380

参考文献 28

[1]	Liu K, Wang BZ, Hao Y, et al. The correlation between migraine and patent foramen ovale[J]. Front Neurol, 11:543485. doi:10.3389/fneur.2020.543485.
[2]	Gollion C, Lerebours F, Barbieux-Guillot M, et al. Cryptogenic ischemic stroke in migraine: Role of patent foramen ovale[J]. Front Pain Res (Lausanne), 3:823595.doi:10.3389/fpain.2022.823595.
[3]	Badea RŞ, Grecu N, Ribigan AC, et al. Headache patterns in patent foramen ovale patients: Beyond migraine with aura[J]. J Neural Transm (Vienna), 2024, 131(7):755-761.doi:10.1007/s00702-024-02760-8.
[4]	Cao W, Shen Y, Zhong J, et al. The Patent foramen ovale and migraine: Associated mechanisms and perspectives from MRI evidence[J]. Brain Sci, 2022, 12(7):941. doi:10.3390/brainsci12070941.
[5]	Zhang Y, Wang H, Liu L. Patent foramen ovale closure for treating migraine: A meta-analysis[J]. J Interv Cardiol, 2022:6456272. doi:10.1155/2022/6456272.
[6]	Zhang QQ, Lu JJ, Yan MY, et al. The efficacy of percutaneous patent foramen ovale closure on migraine: A meta-analysis of randomized controlled trials and observational studies[J]. Biomed Res Int, 2021:6643266. doi:10.1155/2021/6643266.
[7]	Kong R, Yu J, Li J, et al. Transcatheter closure of patent foramen ovale in children with migraine or dizziness[J]. Eur J Pediatr, 2025, 184(9):544. doi:10.1007/s00431-025-06367-3.
[8]	Ben-Assa E, Rengifo-Moreno P, Al-Bawardy R, et al. Effect of residual interatrial shunt on migraine burden after transcatheter closure of patent foramen ovale[J]. JACC Cardiovasc Interv, 2020, 13(3):293-302. doi:10.1016/j.jcin.2019.09.042.
[9]	Ujka K, Pizzuto A, Giordano M, et al. Prevalence, classification, and treatment of residual shunt after patent foramen ovale closure[J]. EuroIntervention, 2025, 21(16):933-941. doi:10.4244/EIJ-D-24-00856. pmid: 40828307
[10]	Nakayama R, Takaya Y, Akagi T, et al. Relationship between patent foramen ovale anatomical features and residual shunt after patent foramen ovale closure[J]. Cardiovasc Interv Ther, 2024, 39(2):200-206. doi:10.1007/s12928-023-00979-y. pmid: 38265606
[11]	Katsianos E, Oikonomou E, Kalogeras K, et al. Residual right-to-left-shunt following transcatheter patent foramen ovale closure: The role of antithrombotic treatment[J]. Curr Pharm Des, 2022, 28(40):3305-3312. doi:10.2174/1381612829666221028095839.
[12]	Deng W, Yin S, McMullin D, et al. Residual shunt after patent foramen ovale closure and long-term stroke recurrence: A prospective cohort study[J]. Ann Intern Med, 2020, 172(11):717-725. doi:10.7326/M19-3583. pmid: 32422058
[13]	Fan JN, Li MF, Zhang BJ, et al. Overlooked trigger of migraine: Clinical significance of small-and medium-shunt patent foramen ovale[J]. Cardiology, 2025, 5:1-10. doi:10.1159/000546696.
[14]	Mi Z, He G, Li C, et al. Efficacy and safety of transesophageal ultrasound-guided patent foramen ovale closure for migraine in adolescents[J]. Front Pediatr, 2023, 11:1296825.doi:10.3389/fped.2023.1296825.
[15]	Qi Y, Zhang Y, Luo X, et al. Efficacy of patent foramen ovale closure for treating migraine: A prospective follow-up study[J]. J Investig Med, 2021, 69(1):7-12. doi:10.1136/jim-2020-001323.
[16]	Witte LS, El Bouziani A, Beijk MAM, et al. Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke[J]. Heart, 2024, 110(19):1172-1179. doi:10.1136/heartjnl-2024-323905. pmid: 39122559
[17]	Khasiyev F, Arsava EM, Topcuoglu MA. Cerebral vasomotor reactivity in migraine: Effect of patent foramen ovale and aerogenic microembolism[J]. Neurol Res, 2020, 42(9):795-804. doi:10.1080/01616412.2020.1775015. pmid: 32496894
[18]	Fu X, Li M. Relationship between migraine and patent foramen ovale observed by contrast-enhanced transthoracic echocardiography[J]. J Coll Physicians Surg Pak, 2023, 33(3):352-354. doi:10.29271/jcpsp.2023.03.352. pmid: 36945169
[19]	Harm T, Zdanyte M, Goldschmied A, et al. Pre-interventional transesophageal echocardiography as a reliable predictor of residual shunt following patent foramen ovale closure[J]. Clin Res Cardiol, 2026, 115(3):484-494. doi:10.1007/s00392-025-02713-5.
[20]	Perdreau E, Jalal Z, Walton RD, et al. Assessment of nit-occlud atrial septal defect occluder device healing process using micro-computed tomography imaging[J]. PLoS One, 2023, 18(4):e0284471. doi:10.1371/journal.pone.0284471.
[21]	Dong B, Li X, Zhang L, et al. Effects of patent foramen ovale in migraine: A metabolomics-based study[J]. J Physiol, 2025, 603(4):809-835. doi:10.1113/JP286772.
[22]	Trabattoni D, Brambilla M, Canzano P, et al. Migraine in patients undergoing pfo closure: Characterization of a platelet-associated pathophysiological mechanism: the LEARNER study[J]. JACC Basic Transl Sci, 2022, 7(6):525-540. doi:10.1016/j.jacbts.2022.02.002. pmid: 35818509
[23]	Li C, Yu Y, Li N, et al. Calcitonin gene-related peptide: A possible biomarker in migraine patients with patent foramen ovale[J]. BMC Neurol, 2024, 24(1):126. doi:10.1186/s12883-024-03615-1. pmid: 38627623
[24]	Grodzka O, Borończyk M, Zduńska A, et al. Migraine and patent foramen ovale: Correlation, coexistence, dependence. A narrative review[J]. Headache, 2026, 66(1):307-321. doi:10.1111/head.15067.
[25]	Thanopoulos BVD, Bompotis GC, Deleanou D, et al. Transcatheter closure of patent foramen ovale using the cocoon occluder: A multicenter retrospective study[J]. Hellenic J Cardiol, 2023, 75:21-25. doi:10.1016/j.hjc.2023.04.011.
[26]	Sun L, Fan Z, Gao J, et al. Association between patent foramen ovale morphology and clinical outcomes following transcatheter closure[J]. Int J Cardiol, 2024, 412:132307. doi:10.1016/j.ijcard.2024.132307.
[27]	Rizza V, Belli M, Stella S, et al. A ‘twice closed’ patent foramen ovale: A case report of percutaneous management of a residual interatrial shunt in a patient with persistent migraine symptoms[J]. Eur Heart J Case Rep, 2024, 8(9):ytae449. doi:10.1093/ehjcr/ytae449.
[28]	Iannetta L, Presbitero P, Onorato EM, et al. Clinical implications of residual shunt after patent foramen ovale closure[J]. Minerva Cardiol Angiol, 2025, 73(3):355-366. doi:10.23736/S2724-5683.24.06456-1.

经导管卵圆孔未闭封堵术后残余分流影响偏头痛疗效评估的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵海娜，闫欣桐，李玉峰，李新毅. 偏头痛患者脑功能磁共振成像研究进展[J]. 临床荟萃, 2018, 33(12): 1102-1104.
[2]	李自平;杨立新;霍清霞. 经颅多普勒超声在小儿偏头痛诊断治疗中的价值[J]. 临床荟萃, 2013, 28(4): 430-431.
[3]	赵永俊;陈春富. 偏头痛类型及性别对患者生活质量影响的调查研究[J]. 临床荟萃, 2013, 28(1): 20-2225.
[4]	陶茵;沈天寒. 氟桂利嗪联合布洛芬治疗青春期青少年偏头痛的疗效观察[J]. 临床荟萃, 2013, 28(1): 90-91.
[5]	麻继红;田军彪. 应用经颅多普勒对偏头痛患者脑血管反应性的观察[J]. 临床荟萃, 2011, 26(19): 1715-1716.
[6]	周国栋;曾德志;周红. 普萘洛尔治疗儿童偏头痛临床观察[J]. 临床荟萃, 2011, 26(12): 1075-1076.
[7]	徐捷. 度洛西汀的神经科应用研究进展[J]. 临床荟萃, 2010, 25(23): 2109-2111.
[8]	彭莉;高旭光. 偏头痛患者超敏C反应蛋白的变化及阿司匹林疗效的观察[J]. 临床荟萃, 2006, 21(3): 169-171.
[9]	赵珊. 复方丹参治疗小儿偏头痛26例[J]. 临床荟萃, 2006, 21(12): 910-910.
[10]	安胜利. 偏头痛患者变应原测定207例临床分析[J]. 临床荟萃, 2005, 20(3): 155-156.
[11]	康英;王育红;智丽敏;贾俊芳. 复方丹参滴丸的临床新应用[J]. 临床荟萃, 2005, 20(10): 596-597.
[12]	崔利坤. 偏头痛的诊断及防治[J]. 临床荟萃, 2004, 19(17): 1020-0.
[13]	赵学喜;蔺怀明;薛凌;尚军;朱海英;胡兴贵. 尼莫地平治疗偏头痛观察分析[J]. 临床荟萃, 2003, 18(1): 38-39.
[14]	王昌铭;彭昌鼎;吉国泰;程相铎;周裕成. 脱敏治疗季节性偏头痛90例效果观察及血清总IgE的变化[J]. 临床荟萃, 2002, 17(8): 478-479.
[15]	赵群峰;裘银虹;汤义平;陈文斌. 泰必利与镁制剂治疗偏头痛72例疗效观察[J]. 临床荟萃, 2001, 16(1): 6-0.